ASCENT-GYN-01 | CT06486441

Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy. Contact: advisory.services@anzgog.org.au

ASCENT-GYN-01 | CT064864412026-07-30T18:58:27+10:00

Symbiotic-GYN-18 | NCT07578649

An Interventional Phase 3, Open Label, Randomized Study To Evaluate Efficacy And Safety of PF-08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent Mismatch Repair (MMR) Proficient Endometrial Cancer. Contact: [...]

Symbiotic-GYN-18 | NCT075786492026-07-22T14:14:27+10:00

RAINFOL-03 | NCT07166094

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer. Contact: advisory.services@anzgog.org.au

RAINFOL-03 | NCT071660942026-07-22T14:12:13+10:00

EN.10/TAPER | NCT05640999

The primary objective of this study is to estimate the rate of pelvic recurrence at 3 years in patients who are treated with de-escalated adjuvant treatment directed by tumour molecular status.

EN.10/TAPER | NCT056409992026-06-12T09:36:53+10:00

XPORT-EC-042

XPORT aims to evaluate the benefit of selinexor in patients with no TP53 alteration advanced or recurrent Endometrial Cancer. Patients will receive either oral selinexor or placebo as maintenance therapy following chemotherapy, until disease progression.

XPORT-EC-0422026-06-12T09:37:22+10:00

ENDO-3 | NCT04073706

ENDO-3 is a randomised controlled trial that compares sentinel lymph node dissection, a commonly performed procedure for the surgical staging of endometrial cancer, to no node dissection. The outcomes from this trial will provide high-level evidence on sentinel lymph node [...]

ENDO-3 | NCT040737062026-03-12T21:29:31+11:00
Go to Top